{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:37:59Z","timestamp":1793644679007,"version":"4.5.1"},"reference-count":78,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutics and Clinical Risk Management"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.2147\/tcrm.2007.3.1.59","type":"journal-article","created":{"date-parts":[[2007,6,19]],"date-time":"2007-06-19T20:52:55Z","timestamp":1182286375000},"page":"59-69","source":"Crossref","is-referenced-by-count":15,"title":["Venlafaxine extended release (XR) in the treatment of panic disorder"],"prefix":"10.2147","volume":"3","author":[{"given":"Kevin","family":"Kjernisted","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"p_1_1","unstructured":"Albano A, Tourian K, Tzanis E, etal 2006. Venlafaxine ER in adolescents with panic disorder [Abstract]. Paper presented at: Anxiety Disorders Association of America (ADAA); March 23-26, Miami, Florida. 355."},{"key":"p_2_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/01.CIR.0000153813.64165.5D","volume":"111","author":"Albert CM","year":"2005","journal-title":"Circulation"},{"key":"p_3_3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hup.602","volume":"19","author":"Allgulander C","year":"2004","journal-title":"Hum Psychopharmacol"},{"key":"p_4_4","unstructured":"[APA] American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, text revised (DSM-IV-TR), 4th ed. Washington, DC: APA."},{"key":"p_5_5","doi-asserted-by":"crossref","unstructured":"Angst J. 1996. Comorbidity of mood disorders: a longitudinal prospective study. Br J Psychiatry Suppl, 31-7.","DOI":"10.1192\/S0007125000298383"},{"key":"p_6_6","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.02255.x"},{"key":"p_7_7","first-page":"5","volume":"62","author":"Ballenger J.","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"p_8_8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15622970209150621","volume":"3","author":"Bandelow B","year":"2002","journal-title":"World J Biol Psychiatry"},{"key":"p_9_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2007-979479","volume":"30","author":"Benazzi F.","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"p_10_10","first-page":"30","volume":"66","author":"Blier P","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"p_11_11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.187.4.352"},{"key":"p_12_12","first-page":"358","volume":"38","author":"Brubacher J","year":"1996","journal-title":"Vet Hum Toxicol"},{"key":"p_13_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/070674370605100104","volume":"51","author":"Canadian Journal","year":"2006","journal-title":"Can J Psychiatry"},{"key":"p_14_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0306-4522(02)00062-3","volume":"112","author":"Cecchi M","year":"2002","journal-title":"Neuroscience"},{"key":"p_15_15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1176\/ajp.145.3.293","volume":"145","author":"Coryell W","year":"1988","journal-title":"Am J Psychiatry"},{"key":"p_16_16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1176\/ajp.151.3.413","volume":"151","author":"Eaton WW","year":"1994","journal-title":"Am J Psychiatry"},{"key":"p_17_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4088\/JCP.v58n0307d","volume":"58","author":"Fawcett J.","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"p_18_18","unstructured":"Ferguson J, Whitaker T, Mangano R, etal 2005; Preventing relapse of panic disorder in adult outpatient responders to venlafaxine XR. Presented at Anxiety Disorders Association of America (ADAA); March 17-21, Seattle, Washington."},{"key":"p_19_19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","volume":"48","author":"Frank E","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"p_20_20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.23.3082"},{"key":"p_21_21","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199702000-00022"},{"key":"p_22_22","doi-asserted-by":"publisher","DOI":"10.1002\/da.1074"},{"key":"p_23_23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/archpsyc.60.11.1125","volume":"60","author":"Goodwin RD","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"p_24_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00002018-200124030-00003","volume":"24","author":"Haddad PM.","year":"2001","journal-title":"Drug Saf"},{"key":"p_25_25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/026988110101500210","volume":"15","author":"Haddad PM","year":"2001","journal-title":"J Psychopharmacol"},{"key":"p_26_26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/0960327197016001031","volume":"16","author":"Hodgman M","year":"1997","journal-title":"Hum Exp Toxicol"},{"key":"p_27_27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4088\/JCP.v58n0403","volume":"58","author":"Katerndahl DA","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"p_28_28","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1161\/01.CIR.89.5.1992","volume":"89","author":"Kawachi I","year":"1994","journal-title":"Circulation"},{"key":"p_29_29","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1161\/01.CIR.90.5.2225","volume":"90","author":"Kawachi I","year":"1994","journal-title":"Circulation"},{"key":"p_30_30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.v63n0302","volume":"63","author":"Kennedy SH","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"p_31_31","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.593"},{"key":"p_32_32","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"p_33_33","unstructured":"Khandker R, Zhang H, Gao B. 2005; Patient-reported quality of life and functionality in panic disorder: venlafaxine, paroxetine, and placebo. Paper presented at: Anxiety Disorders Association of America; March 17-21, Seattle, Washington"},{"key":"p_34_34","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00001"},{"key":"p_35_35","first-page":"62","volume":"35","author":"Levin G","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"p_36_36","first-page":"1","author":"Liebowitz M","year":"2004","journal-title":"Annual Meeting of the American Psychiatric Association"},{"key":"p_37_37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1176\/appi.ajp.159.1.30","volume":"159","author":"MacKinnon DF","year":"2002","journal-title":"Am J Psychiatry"},{"key":"p_38_38","unstructured":"McIntosh A, Cohen A, Turnbull N, etal 2004. Clinical guidelines and evidence review for panic disorder and generalised anxiety disorder. Sheffield: University of Sheffield\/London: National Collaborating Centre for Primary Care."},{"key":"p_39_39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1055\/s-2007-979507","volume":"30","author":"Mekler G","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"p_40_40","unstructured":"Ministry of Health. 2003. Clinical practice guidelines: anxiety disorders. Singapore: Ministry of Health, pp 1-75."},{"key":"p_41_41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145704004080","volume":"7","author":"Morilak DA","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"p_42_42","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(86)90769-0"},{"key":"p_43_43","first-page":"16","volume":"13","author":"Nagy LM","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"p_44_44","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/archpsyc.1989.01810110035005","volume":"46","author":"Nagy LM","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"p_45_45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2869.2005.00447.x","volume":"14","author":"Nissen C","year":"2005","journal-title":"J Sleep Res"},{"key":"p_46_46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1037\/0021-843X.94.2.216","volume":"94","author":"Norton GR","year":"1985","journal-title":"J Abnorm Psychol"},{"key":"p_47_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-0327(89)90080-3","volume":"16","author":"Noyes R, Jr.","year":"1989","journal-title":"J Affect Disord"},{"key":"p_48_48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.1989"},{"key":"p_49_49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","volume":"41","author":"Otton SV","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"p_50_50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0306-4522(02)00364-0","volume":"115","author":"Pardon MC","year":"2002","journal-title":"Neuroscience"},{"key":"p_51_51","doi-asserted-by":"publisher","DOI":"10.1159\/000029018"},{"key":"p_52_52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0248-8663(00)80048-X","volume":"21","author":"Pinzani V","year":"2000","journal-title":"Rev Med Interne"},{"key":"p_53_53","unstructured":"Pollack M, Emilien G, Tzanis E, etal 2004; Short-term treatment of panic disorder with venlafaxine XR and paroxetine. Presented at: World Congress of Women's Mental Health; March 17-20, Washington, DC."},{"key":"p_54_54","unstructured":"Pollack M, Stein DJ, Mangano R, etal 2006; Venlafaxine XR in the shortterm treatment of panic disorder: A pooled analysis of predictors [Abstract]. Presented at: Anxiety Disorders Association of America (ADAA); March 23-26, Miami, Florida"},{"key":"p_55_55","unstructured":"Pollack M, Whitaker T. 2003; Randomized, placebo-controlled trial of venlafaxine XR and paroxetine in the short-term treatment of panic disorder [poster]. Presented at: Anxiety Disorders Association of America (ADAA); March 27-30, Toronto, Canada"},{"key":"p_56_56","unstructured":"Pollack M, Whitaker T, Mangano R, etal 2005; Short-term treatment of panic disorder: a comparison of venlafaxine XR vs paroxetine or placebo. Presented at: Anxiety Disorders Association of America (ADAA); March 17-21, Seattle, Washington."},{"key":"p_57_57","first-page":"667","volume":"32","author":"Pollack MH","year":"1996","journal-title":"Psychopharmacol Bull"},{"key":"p_58_58","first-page":"31","volume":"15","author":"Ramage-Morin PL.","year":"2004","journal-title":"Health Rep"},{"key":"p_59_59","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.5.678.32198"},{"key":"p_60_60","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/j.1440-1614.2003.01254.x","volume":"37","author":"Royal Australian and New Zealand College of Psychiatrists.","year":"2003","journal-title":"Aust N Z J Psychiatry"},{"key":"p_61_61","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0193-953X(18)30146-1","volume":"16","author":"Roy-Byrne P","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"p_62_62","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.176.3.229","volume":"176","author":"Roy-Byrne PP","year":"2000","journal-title":"Br J Psychiatry"},{"key":"p_63_63","first-page":"27","volume":"67","author":"Schatzberg AF","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"p_64_64","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archpsyc.1994.03950050006001","volume":"51","author":"Shear MK","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"p_65_65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1176\/ajp.153.2.213","volume":"153","author":"Sherbourne CD","year":"1996","journal-title":"Am J Psychiatry"},{"key":"p_66_66","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0165-0327(01)00378-0","volume":"69","author":"Simon NM","year":"2002","journal-title":"J Affect Disord"},{"key":"p_67_67","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.5.396"},{"key":"p_68_68","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/00005537-200208000-00005","volume":"112","author":"Staab JP","year":"2002","journal-title":"Laryngoscope"},{"key":"p_69_69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.psychres.2003.10.002","volume":"125","author":"Sullivan GM","year":"2004","journal-title":"Psychiatry Res"},{"key":"p_70_70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/j.1552-4604.1996.tb04183.x","volume":"36","author":"Troy S","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"p_71_71","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/j.1552-4604.1998.tb04455.x","volume":"38","author":"Troy S","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"p_72_72","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00004714-199710000-00006","volume":"17","author":"Tucker P","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"p_73_73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archpsyc.1997.01830160021003","volume":"54","author":"Weissman M","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"p_74_74","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.56.9.794","volume":"56","author":"Weissman MM","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"p_75_75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2190\/9HJ2-VK0H-XJYG-MKQ6","volume":"18","author":"Wulsin LR","year":"1988","journal-title":"Int J Psychiatry Med"},{"key":"p_76_76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0165-1781(00)00119-0","volume":"93","author":"Yeragani VK","year":"2000","journal-title":"Psychiatry Res"},{"key":"p_77_77","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1176\/ajp.148.11.1583","volume":"148","author":"Zandbergen J","year":"1991","journal-title":"Am J Psychiatry"},{"key":"p_78_78","unstructured":"Zhang H, Mallick R, Gao B. 2004. Patient perceptions of quality of life and functionality in panic disorder: A comparison of venlafaxine XR, paroxetine and placebo. Presented at: International Congress of Biological Psychiatry; February 9-13, Sydney, Australia"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T19:13:22Z","timestamp":1548962002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/venlafaxine-extended-release-xr-in-the-treatment-of-panic-disorder-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.2147\/tcrm.2007.3.1.59"],"URL":"https:\/\/doi.org\/10.2147\/tcrm.2007.3.1.59","relation":{},"ISSN":["1176-6336"],"issn-type":[{"value":"1176-6336","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}